Ark Therapeutics has posted a reasonable set of financials for 2008 which saw a narrowing of losses but lower revenues as analysts wait for a possible approval of Cerepro, the UK firm’s gene-based therapy for brain cancer.
Read MoreShire says that it has decided to withdraw a submission to regulators in Europe for Daytrana, its patch for attention deficit hyperactivity disorder.
Read MoreJapan’s Astellas Pharma says it has decided to pulled out of the battle to acquire CV Therapeutics, leaving the field clear for Gilead Sciences.
Read MoreSchering-Plough has been boosted by data from a mid-stage study of its new anti-platelet agent which has shown promise in not increasing the risk of bleeding.
Read MoreThe State of Massachusetts has passed what it calls “tough new rules” governing sales and marketing practices of pharmaceutical and medical device companies doing business there.
Read More
